Crohn's disease doubled its Korean patient count in a decade to 33,238

A doubling over ten years compounds at 7.5% a year ^[14]. That is the pace a drugmaker would use to plan a territory. In headcount the two annual figures are 17,100 patients apart, an average of about 1,710 net additions a year ^[15]. The Health Insurance Review and Assessment Service counted people who sought hospital treatment ^[1]. The report describes biologics as expensive therapies and never says what they cost ^[19]. Anyone sizing Asia as a biologics market off this release is working from volume alone.

The age mix is where the long bill comes from. The two youngest adult cohorts are 56.3% of the total, roughly 18,700 people, and adding the teenagers puts about 23,700 patients under 40 ^[16][17]. Yoon Jong-shin, the singer, has reportedly lived with the disease for more than 30 years, and in 2012 told SBS's "Healing Camp" that 60 centimeters of his small intestine had to be cut out after it narrowed ^[12]. "You came to me some 30 years ago, and I learned your name, Crohn's, 20 years ago," he wrote in a recent social media post disclosing a flare-up ^[13]. His own account puts about ten years between onset and the diagnosis ^[18].

Professor Seo Jung-kuk's team at Chung-Ang University Hospital divided the epidemiology since the first Japanese case in the 1920s into four stages: emergence, a sharp rise in incidence, accumulation of prevalence, and equilibrium ^[6]. In the team's own naming, the third stage is where new diagnoses settle and the treated population keeps growing. A Crohn's patient diagnosed at 25 stays in the count. Korea is in the latter part of the second stage, with both new and existing patients accumulating ^[7].

"In clinical practice, the patient population is becoming increasingly diverse and complex, with new diagnoses rising not only among young patients but also among older adults," Seo told Newsis ^[10]. His team recommended infrastructure for early diagnosis, multidisciplinary care, treatment tailored to each stage of life, and reasonable drug pricing and reimbursement policies to ease the financial burden of expensive therapies such as biologics ^[11].

Detection could break the growth reading. The figure counts treated patients ^[1], and better diagnosis and coding can lift a treated count without any change in true incidence. The drivers the team lists include animal fat and refined carbohydrate intake and infant antibiotic use ^[8]; those are associations observed across five Asian populations ^[5], and the cause of the disease is still unknown ^[4]. The reimbursement rate is the other. If Korea prices IBD biologics low, a 7.5% compound rise in patients ^[14] does not deliver a 7.5% rise in anyone's revenue. The prescribing clinicians have asked for pricing policy that leans that way ^[11].

The release establishes a patient curve, and that curve is the part I would treat as settled. A per-patient reimbursement figure would settle the rest, and that figure comes out of a pricing decision.